Health Affairs · 2021 · 92 citations · 38 references
NursingPharmaceutical PolicySocial PolicyMedicaid PolicySubstance Use DisordersSubstance Use PreventionMedication AccessOpioid PolicyOpioid RegulationOpioid TherapyOpioid Use DisorderOverdose PreventionBuprenorphine RegulationBuprenorphine TreatmentMedication-related DeathsMethadone RegulationOffice-based Opioid TreatmentOpioid Use Disorder Treatment AccessOpioid Use Disorder Treatment RetentionOpioid-related Mortality
Social discourse about the opioid crisis in the US has focused on White populations, even though opioid-related deaths have grown at a higher rate among people of color than among non-Hispanic White people in recent years. Medications for opioid use disorder (OUD) are the gold standard for treating OUD and preventing overdose but are underused among people with OUD, with disproportionately low treatment initiation and retention among people of color. Methadone, which is highly stigmatized and has a more burdensome treatment regimen, is the predominant medication for OUD available to people of color. To address disparities in the initiation and retention of treatment using medication for OUD, policy makers should consider strategies such as Medicaid expansion, increased grant funding for federally qualified health centers to provide buprenorphine treatment, retention of temporary telehealth policies that allow remote buprenorphine induction, and regulatory changes to allow methadone treatment in office-based practices.
38
Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder
Sarah E. Wakeman, Marc R. Larochelle, Omid Ameli et al. · JAMA Network Open · 2020 · 975 citations · Full text
Buprenorphine Treatment Divide by Race/Ethnicity and Payment
Pooja Lagisetty, Ryan Ross, Amy S. B. Bohnert et al. · JAMA Psychiatry · 2019 · 468 citations · Full text
The Opioid Crisis in Black Communities
Keturah James, Ayana Jordan · The Journal of Law Medicine & Ethics · 2018 · 309 citations